Typically, the individual daily insulin requirement in adults and children is 0.5 to 1 U / kg body weight. With the introduction of the drug before a meal, insulin requirements may be provided by the drug nandrolone phenylpropionate by 50-70%, the rest is provided by the need for insulin by insulin prolonged action. Increasing physical activity of the patient, a change in eating habits or concomitant diseases can lead to the need for dose adjustment.
Has more rapid onset and shorter duration of action than soluble human insulin With quicker onset of action, be administered, usually immediately before meal can be administered shortly after a meal as required. Due to shorter duration of action compared with human insulin, the risk of nocturnal hypoglycemia in patients receiving below.
Special groups of patients
As with other insulin formulations, elderly patients and patients with renal or hepatic insufficiency should more carefully monitor the concentration of blood glucose and insulin dose aspart adjusted individually.
Children and adolescents
Use instead of soluble human insulin in children is preferable in the case when you need a quick onset of action of the drug, for example, when a child is difficult to comply with the required time interval between injection and meal.
Transfer from other insulin products
When transferring a patient from other insulin preparations in the , you may need a dose adjustment and basal insulin.
Inserted subcutaneously in the anterior abdominal wall, the thigh, shoulder, deltoid or gluteal region. Injection sites within the same area of the body need to be changed regularly to reduce the risk of lipodystrophy. As with all insulin preparations in subcutaneous abdominal wall provides a more rapid absorption compared with administration to other places. The duration of action is dose-dependent, the injection site, blood flow rate, temperature and level of physical activity. However, more rapid onset of action compared to soluble human insulin is retained regardless of the localization of the site of injection. Can be used for extended subcutaneous insulin infusion (CSII) in insulin pumps developed for infusion of insulin. CSII should be made in the abdominal wall. infusion site should be changed periodically. If you use an insulin pump infusion, should not be confused with other types of insulin.
Patients using CSII should be fully trained in the use of the pump corresponding to the reservoir and pump system for pipes. The infusion set (tubing and catheters) should be changed in accordance with the user’s manual that came with the infusion set.
Patients receiving using CSII should be available in case of additional insulin infusion system failure.
If necessary, may be administered intravenously, but only by qualified medical personnel. For intravenous infusion sets are used with medication NovoRapid® 100 U / ml with a concentration of 0.05 U / ml to 1 U / ml insulin aspart in 0.9% sodium chloride; 5% dextrose or 10% dextrose solution containing 40 mmol / l potassium chloride, using polypropylene containers for infusions. These solutions are stable at room temperature for 24 hours. Despite the stability over time, a certain amount of insulin absorbed material initially infusion system. During the infusion of insulin you need to constantly monitor the blood glucose concentration.
The most common adverse reaction is hypoglycaemia. The incidence of side effects varies depending on the patient population, dosing regimen of the drug and glycemic control (see. Below).
At the initial stage insulin disorders can occur refraction, edema and injection site reactions of the drug (pain, redness, hives, inflammation, bruising, swelling and itching at the injection site). These symptoms are usually transient. The rapid nandrolone phenylpropionate improvement in glycemic control may lead to the condition “acute painful neuropathy”, which is usually reversible. Intensification of insulin with dramatic improvement in control of carbohydrate metabolism may lead to a temporary deterioration in the state of diabetic retinopathy, while long-term improvement of glycemic control reduces the risk of progression of diabetic retinopathy. Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo.